InfiCure Bio AB is located in Umeå, Sweden on Tvistevägen 48C. InfiCure Bio AB is rated 3 out of 5 in the category biotechnology in Sweden. Development of fibrosis is associated with several disorders as well as life-style factors and affects multiple organs including the heart, liver, lungs and kidneys. Fibrosis is the formation of excess connective tissue in the affected organ, which in the end leads to organ failure. While contributing to approximately 40 percent of deaths in the industrial world, no effective anti-fibrotic drugs are available on the market. One caveat in the development of anti-fibrotic drugs is the lack of good and reliable pre-clinical models for testing of substances under development. InfiCure Bio has a unique pre-clinical model, which spontaneously develops fibrosis in multiple organs. The model will be used to test the effect of anti-fibrotic substances under development. The company is based on the access to this unique pre-clinicalmodel in combination with the inventors’ expertise in the field of inflammation and fibrosis and their experience in effect testing. The business strategy is to identify and approach drug developing companies with focus on anti-fibrotic substances and offer them to test their substances in this unique model.
Company size
1-10 employees